Type 2 diabetes management in 2019: the same cost-efficiency ratio? The diabetologist’s perspective

Michel P. Hermans Published in the journal : March 2019 Category : Session de Diabétologie

Summary :

The results of 14 prospective randomized clinical trials designed to verify the macrovascular safety of various classes of anti-hyperglycemic agents in T2DM, such as DPP4-inhibitors, SGLT2-inhibitors, and GLP-1 receptor agonists, have confirmed their safety for use in all studies; for some molecules, such as empagliflozine, canagliflozine, dapagliflozine, liraglutide, semaglutide, albiglutide and dulaglutide, the data revealed a beneficial pleiotropic effect on the primary endpoint, usually consisting of a composite of CV death, non-fatal infarction, and non-fatal stroke.

Key Words

Type 2 diabetes macroangiopathy, microangiopathy, safety; cardiovascular, anti-hyperglycemic agents